Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation-Reference-Cited by-同舟云学术

Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation

Published:2022-06 Issue:6 Volume:22 Page:1646-1657
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:American Journal of Transplantation

Author:

Schmidt Hartmut H.^ORCID,Wixner Jonas,Planté-Bordeneuve Violaine,Muñoz-Beamud Francisco,Lladó Laura^ORCID,Gillmore Julian D.,Mazzeo Anna^ORCID,Li Xingyu,Arum Seth,Jay Patrick Y.,Adams David

Publisher

Elsevier BV

Subject

Pharmacology (medical),Transplantation,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajt.17009

Reference50 articles.

1. Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study;Adams;Neurology.,2015

2. Novel drugs targeting transthyretin amyloidosis;Hanna;Curr Heart Fail Rep.,2014

3. Cardiac amyloidosis: updates in diagnosis and management;Mohty;Arch Cardiovasc Dis.,2013

4. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis;Adams;N Engl J Med.,2018

5. Inotersen treatment for patients with hereditary transthyretin amyloidosis;Benson;N Engl J Med.,2018

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery;International Journal of Pharmaceutics: X;2024-12

2. Assessing the effectiveness and safety of Patisiran and Vutrisiran in ATTRv amyloidosis with polyneuropathy: a systematic review;Frontiers in Neurology;2024-09-02

3. Recommendations update for the diagnosis and treatment of transthyretin variant amyloidosis (ATTRv);Medicina Clínica (English Edition);2024-09

4. Specific Therapy in Transthyretin Amyloid Cardiomyopathy;Heart Failure Clinics;2024-07

5. Amyloid Neuropathy: From Pathophysiology to Treatment in Light‐Chain Amyloidosis and Hereditary Transthyretin Amyloidosis;Annals of Neurology;2024-06-24